Companies Sense Biodetection

Redefining diagnostics at the point-of-care


The recent pandemic illustrated the importance of widely available, accurate, rapid and simple infectious disease testing at the point-of-care.

Sense Biodetection’s hardware platform for instrument-free testing combined with its ground-breaking proprietary chemistry reagents have led to the creation of a suite ofeasy to use molecular diagnostic tests that are ready to use in any setting whilst providing a performance level comparable to that of a laboratory-based test. Sense Biodetection was acquired by Sherlock Biosciences in February 2023.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More